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Abstract T cell epitopes derived from polymorphic proteins
or from proteins encoded by alternative reading frames
(ARFs) play an important role in (tumor) immunology.
Identification of these peptides is successfully performed with
mass spectrometry. In a mass spectrometry-based approach,
the recorded tandem mass spectra are matched against
hypothetical spectra generated from known protein sequence
databases. Commonly used protein databases contain a
minimal level of redundancy, and thus, are not suitable data
sources for searching polymorphic T cell epitopes, either in
normal or ARFs. At the same time, however, these databases
contain much non-polymorphic sequence information, there-
by complicating the matching of recorded and theoretical
spectra, and increasing the potential for finding false positives.
Therefore, we created a database with peptides from ARFs
and peptide variation arising from single nucleotide poly-
morphisms (SNPs). It is based on the human mRNA
sequences from the well-annotated reference sequence
(RefSeq) database and associated variation information
derived from the Single Nucleotide Polymorphism Database
(dbSNP). In this process, we removed all non-polymorphic
information. Investigation of the frequency of SNPs in the
dbSNP revealed that many SNPs are non-polymorphic
“SNPs”. Therefore, we removed those from our dedicated
database, and this resulted in a comprehensive high quality
database, which we coined the Human Short Peptide Variation
Database (HSPVdb). The value of our HSPVdb is shown by
identification of the majority of published polymorphic SNP-
and/or ARF-derived epitopes from amass spectrometry-based
proteomics workflow, and by a large variety of polymorphic
peptides identified as potential T cell epitopes in the HLA-
ligandome presented by the Epstein–Barr virus cells.
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Introduction
T cell-mediated immunotherapy is an attractive treatment
of cancer as it exploits the potential of cytolytic T cells
to specifically recognize antigens that are selectively
expressed on tumor cells (Storb 2003; Hambach and
Goulmy 2005; Kessler and Melief 2007; Falkenburg et al.
2003; Bleakley and Riddell 2004; Eisenlohr 2007). The
enormous specificity of T cells involved in killing tumor
cells makes this kind of treatment very attractive. An
excellent example is the powerful graft-versus-leukemia
(GVL) effect witnessed after allogeneic hematopoietic
stem cell transplantation. GVL is characterized by remis-
sion of a hematological malignancy coinciding with the in
vivo expansion of tumor-specific T cells. These T cells
react to a patient-specific epitope presented in human
leukocyte antigen (HLA) molecules on tumor cells (Marijt
et al. 2003; van Bergen et al. 2007). T cell epitopes are
peptides with a length of generally 8–11 amino acids. T
cells are capable of distinguishing epitopes differing by
only one amino acid, caused by a single nucleotide
difference between patient and donor (Spierings et al.
2007). T cell epitopes, identified to play a role in (tumor)
immunology, may arise from regular reading frames, but
can also be encoded by alternative reading frames (ARFs)
(Ho et al. 2006). Given the need for therapeutically useful
T cell epitopes, the identification of new epitopes is of
unceasing importance. The identification of T cell epitopes
has been achieved with an array of methods, among which
mass spectrometry is one of the most prominent tech-
niques (Engelhard 2007; Hillen and Stevanovic 2006;
Nesvizhskii et al. 2007). Peptide identification by tandem
mass spectrometry is most successfully applied in an ever
increasing number of proteomics studies. In a typical high
throughput proteomics/ligandomics setting (Oliveira et al.
2010), the experimentally determined tandem mass spectra
are matched against a database of hypothetical spectra
generated from known peptide sequences using search
engines like Mascot (Perkins et al. 1999) and Sequest (Eng
et al. 1994).
For mass spectrometry-based identification of epitopes
from polymorphic proteins, like minor histocompatibility
antigens (MiHA) and peptides arising from ARFs, the
commonly used protein databases like UniProt (UniProt
2008), IPI (Kersey et al. 2004) and RefSeqP (Pruitt et al.
2007) are unsuitable data sources, since these display very
incomplete information about polymorphisms. Most of
the published polymorphic MiHA are, therefore, not
present in the standard protein databases, used in mass
spectrometry-based workflows. Several strategies have
been employed to address this problem (MSIPI (Schandorff
et al. 2007), PepHum (Edwards 2007)), each with its own
merits and limitations, trying to find the right balance
between database size and completeness. In addition, there
is a wealth of ligand and/or epitope information databases
(Salimi et al. 2010), but these are not applicable in mass
spectrometry (MS)-based workflows. Knowing that cus-
tomized search databases that provide detailed control
over the search space can vastly outperform standard
strategies (Reisinger and Martens 2009), we designed a
database dedicated to MiHA, thereby improving the chance
of their identification in a proteomics type of experimental
set up.
Our approach is based on the coding potential of the
human genome, including its documented variations, as
described in the RefSeq database. We chose RefSeq
because it contains minimal redundancy, while still
retaining splice variants, incorporates single nucleotide
polymorphism (SNP) data from Single Nucleotide Poly-
morphism Database (dbSNP) (Sherry et al. 2001), which
are richly annotated. We have created a database that
contains all possible short peptides in different reading
frames from a non-redundant mRNA set, combined with
the known and annotated variations/SNPs. In this process,
we removed all non-polymorphic information. Investiga-
tion of the frequency of SNPs in the dbSNP revealed that
many of these SNPs are non-polymorphic “SNPs”.
Therefore, we removed those from our dedicated database
as well, and this resulted in a high quality comprehensive
polymorphic peptide database. Centered on the amino acid
polymorphisms of non-synonymous SNPs, our dedicated
Human Short Peptide Variation Database (HSPVdb) out-
performs existing databases in MS/MS-based T cell
epitope identification.
The value of our HSPV database is shown by identifi-
cation of the majority of published polymorphic SNP- and/
or ARF-derived epitopes from a mass spectrometry-based
proteomics workflow, as well as by a large variety of
polymorphic peptides identified as potential T cell epitopes
in the HLA-ligandome presented by EBV cells.
Materials and methods
Database preparation
The HSPVdb consists of peptides derived from genomic
sequence variations. The database only contains peptides of
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seven amino acids or longer. The RefSeq database release
32 was downloaded from the NCBI FTP site and indexed
using our local SRS installation (Etzold et al. 1996), (http://
srs.bioinformatics.nl). The human mRNA subsection of
RefSeq was extracted by selecting records with molecule
type “mRNA” and organism source “Homo sapiens”. The
resulting list of RefSeq records was subsequently processed
using a series of Perl scripts.
To create the peptides derived from genomic sequence
variations, we made use of the variation annotations that
were added to RefSeq by the dbSNP staff. Variations
found in the 5′ and 3′ UTRs were purposely included to
allow detection of T cell epitopes derived from ARFs.
For each annotated variation, the nucleotide sequences
corresponding to the different alleles were generated.
Instead of duplicating the complete mRNA sequence
for each allele, we took a fragment starting from 30
nucleotides upstream and ending 32 nucleotides down-
stream of the variation. The three forward reading frames
of each allele were translated to amino acid sequences.
This typically results in three peptide sequences of 20
amino acids. Translation ignored the presence or absence
of start codons. Codons that could not be translated to a
single amino acid due to ambiguous nucleotides were
translated to a stop codon. The amino acid translation was
split on stop codons to get peptides derived from a
continuous reading frame. Only the peptides, including
the variation were kept in the database. To minimize
redundancy, a translation for an allele was only included
when the variation gives rise to a change in amino acid
sequence (non-synonymous SNPs). This part of the
database is optimized for finding peptides in the size
range between 8 and 11 amino acids, but databases
containing other peptide lengths can be produced at
will. The database presented here consists of 20-mer
peptides.
Each peptide sequence that was created, was stored as
a separate database record and annotated with the ID of
the originating mRNA sequence and the location of its
encoding reading frame. If the RefSeq entry contains a
coding sequence (CDS), the protein identifier and the
position of that CDS on the mRNA with corresponding
protein identifier, were added as annotation to the
database record. For variations, we included the
corresponding dbSNP identifiers, the positions of the
variations, the nature of the amino acid changes and the
percentage heterozygosity. If a variation causes an amino
acid substitution, a SAP (single amino acid polymor-
phism), the possible amino acids were listed. Insertions
or deletions were annotated as “in/del”. The resulting
database was stored as a flat file in FASTA format for
mass spectrometry-based proteomics purposes. This
HSPVdb is fully dedicated to finding polymorphic
epitopes. To reduce the size of this database, all duplicate
amino acid sequences were deleted. These peptides
contain both polymorphisms for each position, thereby
describing all possible SNP information.
Subsets of the HSPV database were created based on
reported heterozygosity. Three heterozygosity categories
were defined: 0/1, unknown, all others. Additionally, for all
categories ARFs were either included or left out.
Peptides for which the encoding DNA sequence is not
part of the RefSeq-annotated open reading frame are
labeled as alternative reading frame or ARF peptides.
These include CDS that are in a different reading frame
and sequences that are located up- or downstream of the
annotated open reading frame.
SNP genotyping assays
Genomic DNA was isolated from 192 HLA A*0201-
positive patient and donor samples (peripheral blood
mononuclear or bone marrow cells) by the Gentra Systems
PUREGENE genomic isolation kit (Biocompare, San
Francisco, CA). SNPs rs4848158, rs61378134, rs36
023150, rs11540526, rs11554279, rs35958189,
rs56013141, rs11541290, rs34422048, rs11541416,
rs28659989, rs2070159, rs4261080, rs11557142,
rs11555631, rs11479605, rs11541519, rs5030742,
rs11548263 were analyzed using a KASPar assay with
allele-specific primers labeled with VIC and FAM dyes,
(KBioScience, Hoddesdon, UK). Genotyping was per-
formed according to manufacturer’s instructions.
Illumina custom array was used for genotyping rs10960,
rs1143138, rs12986002, rs34669146, rs1047844,
rs11266765, rs11539866, rs11541416, rs11541519,
rs11542419, rs11542836, rs11544489, rs11545551,
rs11548082, rs11553285, rs11553982, rs11554156,
rs11554279, rs11555631, rs11557142, rs11558570,
rs13202878, rs17848351, rs17851857, rs17853301,
rs17853718, rs1803181, rs2070159, rs2261324,
rs28934887, rs28935171, rs28940302, rs3180961,
rs34136999, rs34418712, rs3962697, rs4848158,
rs5030742, rs6112008, rs6686209, rs6794514
Genotyping was performed according to manufacturer’s
instructions.
Sample preparation for test set
Peptide synthesis
Peptides were synthesized by standard Fmoc chemistry on a
Syro II peptide synthesizer as described previously (Hiemstra
et al. 1997). The integrity of the peptides was checked by
reversed-phase high-performance liquid chromatography
(HPLC) and mass spectrometry.
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Liquid chromatography–mass spectrometry
The peptides studied are listed in Table 1. These are
minor histocompatibility antigens as identified by different
research groups around the world. A more complete listing
of MiHA can be found at http://www.lumc.nl/dbminor. To
perfectly mimic the conditions used in a normal mass
spectrometry-based HLA-ligand identification process, all
peptides included in Table 1 were measured by on-line
chromatography/mass spectrometry (see below), and tandem
mass spectra were recorded of their singly, doubly, and triply
charged form. Subsequently, a selection of relevant charge
states was made for each peptide, and charge states with a
substantial contribution to the overall intensity only were
used to construct a Mascot generic file (MGF) containing 31
tandem mass spectra, see Table 2.
Sample preparation for determination of the EBV-LCL
ligandome
Cell collection, preparation, and HLA elutions
Peripheral blood samples were obtained from healthy
donors after approval by the Leiden University Medical
Center Institutional Review Board and informed consent
according to the Declaration of Helsinki. Mononuclear cells
(MNC) were isolated by Ficoll-Isopaque separation and
cryopreserved. Stable Epstein–Barr virus (EBV)-transformed
B cell lines (EBV-LCL) were generated using standard
procedures. EBV-LCL and HeLa cells were cultured in
Iscove’sModified Dulbecco’sMedium (IMDM, BioWhittaker,
Verviers, Belgium) supplemented with 10% bovine fetal
serum (FBS, BioWhittaker).
Peptide isolation
Peptide isolation was performed with protein A beads (GE
healthcare) covalently linked to the major histocompatibilty
complex (MHC) class I mAb W6/32 (3 mg W6/32 on 1 ml
of ProtA sepharose) using dimethyl pimelimidate according
to the standard protocol (Stepniak et al. 2008).
The complex MHC-peptide pool was prefractionated on
a C18 RP-HPLC system (2 mm×15 cm; Reprosil-C18-AQ
3 um; Dr. Maisch GmbH, Ammerbuch, Germany), using a
gradient 0–60% A to B. A: water, 5% Acetonitrile (ACN),
0.1% TFA, B: ACN, 0.1% TFA.
Liquid chromatography–mass spectrometry
Peptide fractions were reduced to near dryness and
resuspended in 95/3/0.1 v/v/v water/acetonitrile/formic acid.
These resuspended fractions were analyzed by on-line
nano-HPLC mass spectrometry with a system described
by Meiring et al (Meiring et al. 2002). Fractions were
injected onto a precolumn (100 um×15 mm; Reprosil-Pur
C18-AQ 3 um, 5 um, Phenomenex) and eluted via an
analytical nano-HPLC column (15 cm×50 um; Reprosil-
Pur C18-AQ 3 um). The gradient was run from 0% to 50%
Table 1 Overview of known MiHA used as a test set in this study. It
displays the epitope name and the HLA-molecule it is presented in. In
addition, its immunogenicity is indicated together with the gene name
and the polymorphisms are indicated. aNames according to http://
www.lumc.nl/dbminor
Epitope namea / HLA Sequence Remarks Gene polymorphic AA dnSNP entry
HA1 / A2 VLHDDLLEA immunogenic HMHA1 VL[R/H]DDLLEA rs1801284
HA2 / A2 YIGEVLVSV immunogenic MYO1G YIGEVLVS[V/M] rs61739531
HA3 / A1 VTEPGTAQY immunogenic AKAP13 V[M/T]EPGTAQY rs2061821
HA8 / A2 RTLDKVLEV immunogenic KIAA0020 [R/P]TLDKVLE[V/I] rs2270891
HA1 / B60 KECVLHDDL immunogenic HMHA1 KECVL[R/H]DDL rs1801284
LB-ADIR-1 F / A2 SVAPALALFPA immunogenic;
ARF in 5’UTR
TOR3A (ADIR) SVAPALAL[F/S]PA rs2296377
LB-ADIR-1 S / A2 SVAPALALSPA allelic counterpart
CTSHr / A31 ATLPLLCAR immunogenic CTSH ATLPLLCA[G/R] rs2289702
CTSHr / A33 WATLPLLCAR immunogenic CTSH WATLPLLCA[G/R] rs2289702
ACC1y / A24 DYLQYVLQI immunogenic BCL2A1 DYLQ[C/Y]VLQI rs1138357
ACC1c / A24 DYLQCVLQI immunogenic
ACC1c+ cystinylated DYLQCVLQI immunogenic
HB1h / B44 EEKRGSLHVW immunogenic HMHB1 EEKRGSL[H/Y]VW rs161557
ACC2d / B44 KEFEDDIINW immunogenic BCL2A1 KEFED[G/D]IINW rs3826007
ACC2g / B44 KEFEDGIINW allelic counterpart
LB-ECGF1-1 H/B7# RPHAIRRPLAL immunogenic; ARF TYMP (ECGF1) RP[H/R]AI[R/C]RPLAL no entry; rs1061205
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solvent B (10/90/0.1 v/v/v water/acetonitrile/formic acid) in
90 min. The nano-HPLC column was drawn to a tip of
approximately 5 um and acted as the electrospray needle of
the MS source.
The mass spectrometer was an LTQ-FT Ultra
(Thermo, Bremen, Germany) and was operated in data-
dependent mode, automatically switching between MS
and MS/MS acquisition. Full scan mass spectra were
acquired in the FT-ICR with a resolution of 25,000 at a
target value of 5,000,000. The two most intense ions
were then isolated for accurate mass measurements by a
selected ion monitoring scan in FT-ICR with a resolution
of 50,000 at a target accumulation value of 50,000. The
selected ions were then fragmented in the linear ion trap
using collision-induced dissociation at a target value of
10,000. In a post analysis process, raw data were
converted to peak lists using Bioworks Browser software,
Version 3.1. For peptide identification, MS/MS data were
submitted to the human IPI database using Mascot
Version 2.2.04 (Matrix Science) with the following
settings: 2 ppm and 0.8-Da deviation for precursor and
fragment masses, respectively; no enzyme was specified.
The Mascot output files were loaded into Scaffold (http://
www.proteomesoftware.com) and exported to Excel as
peptide reports and duplicates were removed.
Results
To investigate the value of our database, we studied two
sets of samples. First, a test set comprising approximately
30% of all MiHA known today, as listed in Table 1, and
second, a set of peptides eluted from HLA from an EBV-
cell line.
Table 2 Summary of the searches with the test set of known MiHA
against the IPI, MSIPI, PepHum, and HSPV database. The peptide names
and sequences are given together with the charge of the precursor,
submitted to tandem mass spectrometry. For each database, three
columns are displayed: (1) whether the peptide is present in the database
(Pr?), followed by (2) the mascot ion score assigned to the tandem mass
spectrum (black filling if the mascot ion score is above the threshold of
the search), and (3) the evaluation, i.e., was the tandem mass spectrum
matched to the correct peptide (black filling and (Y) if correct, and
above the mascot threshold (cut-off score), gray filling if correct and
below (ye) the mascot threshold. In short, the blacker the better. The
HSPVdb scores very well, due to its reduced format in combination
with a high density of relevant SNP information. Wr wrong interpre-
tation of MS2 spectrum; np no matching/no proposal from mascot
search. aNames according to http://www.lumc.nl/dbminor. #Charge state
4+ was the most abundant in the charge distribution of peptide LB-
ECGF-1H, but its MS2 spectrum was of such poor quality that it was
not included for database searching. LB-ADIR peptides are from an
ARF. ACC1+ Cys represents a special case in which the cysteine
residue in the epitope can be modified by formation of an S–S bridge
with free cysteines. This is relevant for both in vivo recognition and
mass spectrometric interpretation
Database IPI369 MSIPI367 PepHum HSPVdb 
Mass accuracy (ppm) 1 1 1 1 
Mascot cut-off score 37 37 38 38 44 44 28 28
Peptide name* Sequence Charge Pr? sco int Pr? sco int Pr? sco int Pr? sco int 
CTSHr A31 ATLPLLCAR 2 10 wr Y 42 Y Y 42 ye Y 42 Y
CTSHr A33  ATLPLLCAR 1 np Y np Y 8 ye Y np
HA3t A1 VTEPGTAQY 2 12 wr Y 34 ye Y 34 ye Y 34 Y
HA3t A1 VTEPGTAQY 1 9 wr Y 18 ye Y 18 wr Y 18 ye
HA2v A2  YIGEVLVSV 1 Y 18 wr Y 18 wr Y 28 wr Y 16 ye
LB-ADIR-1S  A2 SVAPALALSPA 2 22 wr 22 wr Y 48 Y Y 48 Y
LB-ADIR-1S  A2 SVAPALALSPA 1 13 wr 13 wr Y 34 wr Y 8 wr 
HA1h A2  VLHDDLLEA 2 28 wr Y 28 wr Y 28 wr Y 15 ye
HA1h A2  VLHDDLLEA 1 26 wr Y 40 Y Y 40 ye Y 40 Y
LB-ADIR-1F A2  SVAPALALFPA 2 17 wr 17 wr 28 wr Y 66 Y
LB-ADIR-1F A2  SVAPALALFPA 1 25 wr 25 wr 29 wr Y 4 wr 
HA1h B60  KECVLHDDL 2 14 wr Y 36 ye Y 36 ye Y 36 Y
HA1h B60  KECVLHDDL 1 5 wr Y 29 ye Y 29 ye Y 29 Y
HA8rv A2  RTLDKVLEV 3 Y 37 Y Y 37 ye Y 37 ye Y 37 Y
HA8rv A2  RTLDKVLEV 2 Y 34 wr Y 34 wr Y 34 wr Y 30 Y
HA8rv A2  RTLDKVLEV 1 Y 32 ye Y 32 ye Y 32 ye Y 32 Y
ACC1c   DYLQCVLQI 2 Y 50 Y Y 50 Y Y 50 Y Y 50 Y
ACC1c   DYLQCVLQI 1 Y 36 wr Y 36 wr Y 40 wr Y 15 ye
CTSHr A33  WATLPLLCAR 2 8 wr Y 37 ye Y 37 ye Y 37 Y
ACC1y BCL2A1-A24  DYLQYVLQI 2 27 wr Y 58 Y Y 58 Y Y 58 Y
ACC1y BCL2A1-A24  DYLQYVLQI 1 22 wr Y 25 ye Y 25 ye Y 25 ye
ACC1c+cys DYLQCVLQI 2 Y 42 Y Y 42 Y Y 42 ye Y 42 Y
ACC1c+cys DYLQCVLQI 1 Y 36 ye Y 36 ye Y 36 ye Y 36 Y
HB1h  B44  EEKRGSLHVW 3 Y 10 wr Y 10 wr Y 13 wr Y 6 ye
HB1h  B44  EEKRGSLHVW 2 Y 16 ye Y 16 ye Y 16 wr Y 16 ye
ACC2g BCL2A1-B44   KEFEDGIINW 2 Y 48 Y Y 48 Y Y 48 Y Y 48 Y
ACC2g BCL2A1-B44   KEFEDGIINW 1 Y 34 ye Y 34 ye Y 34 ye Y 34 Y
LB-ECGF-1H B7# RPHAIRRPLAL 3 5 wr 5 wr 16 wr 3 wr 
LB-ECGF-1H B7 RPHAIRRPLAL 2 np np 4 wr np 
ACC2d BCL2A1-B44  KEFEDDIINW 2 17 wr Y 39 Y Y 39 ye Y 39 Y
YACC2d BCL2A1-B44  KEFEDDIINW 1 15 wr Y 45 Y Y 45 Y Y 45
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Validation of HSPVdb with a test set of known MiHA
Our test set of known polymorphic peptides and allelic
counterparts were synthesized and measured in standard
on-line nanoHPLC/MS experiments, as in our normal
proteomics workflow on HLA-ligands (Oliveira et al.
2010). Of all significantly occurring charge states, tandem
spectra were recorded. Tandem mass spectra of varying
quality are present in this dataset, reflecting a “real-world”
situation, where the spectral quality depends on intrinsic
peptide properties. A combined peak list was constructed
from these spectra for searching the databases used in this
work. This led to a set of 31 experimental tandem MS
derived from 15 peptides (Table 2).
For validation of our HSPVdb, we compared it to the
MSIPI and PepHum databases that were specifically
constructed to address the lack of peptide variation in
common databases like IPI. A summary of the databases
used in this study is shown in Table 3.
The HSPVdb is similar to the size of the IPI and MSIPI
databases, but it includes all SNP information in all forward
and ARFs (MSIPI: 170.242 SNPs; HSPVdb: 380.182
SNPs). When leaving out the alternative reading frame
information (i.e., HSPVdb subset 1, see Table 3), the size of
our HSPVdb is reduced to only 25% of the size of IPI and
MSIPI, which is of great importance when searching
databases.
The test set containing the tandem mass spectra of
known MiHA was searched against the IPI, MSIPI,
PepHum, and our HSPVdb. Searches were performed using
the Mascot search engine (Matrix science), with various
settings for mass accuracy (1, 2, 5, 10, and 50 ppm)
representing the mass accuracy of various MS and/or
experimental set ups. The enzyme setting was “none”. It
is important to note that in the elucidation of HLA-ligands,
the peptide termini are unknown in contrast to the vast
majority of cases in standard proteomics experiments, in
which peptide matching against databases can be done with
an additional and very stringent condition, namely an
enzyme cleavage site (in most cases, trypsin). In the
standard proteomics approach, the enzyme restriction has
an enormous positive impact on specificity and search time.
For the sequencing of T cell epitopes, enzyme restriction is
not applicable. However, for binding to the presenting HLA
molecule, HLA-ligands have to satisfy certain conditions
imposed by the HLA molecule, the binding motif. This
binding motif can be used as additional help to some extent
to assess the value of the matched sequence by the search
engine. In addition, netMHC, http://www.cbs.dtu.dk/
services/NetMHC/, could be applied to some extent, but
neither of the two can be directly applied in the database
search as a fixed condition. The best proof of a correct
peptide assignment, in spite of improvements in peptide
matching algorithms, is still the comparison of the tandem
spectrum of the proposed eluted epitope with its synthetic
counterpart.
All output of the Mascot search engine was assessed
manually, and a summary of the results for a 1-ppm mass
accuracy is shown in Table 2, and a full report of the
searches is given in Supplementary Table 1.
Table 2 shows a selection of the searches in the four
databases with a 1-ppm mass measurement accuracy. For
every individual tandem mass spectrum, the Mascot ion
score is reported. The results from the database search were
Table 3 Overview of the databases used in this study, listing the
number of entries and the number of amino acid residues present in
each database. In addition, the presence of ARFs and the (type of)
SNP information in the various databases is indicated. The number of
residues of each database relative to the IPI database and the relative
size of the HSPV subsets is given. The number of SNPs in MSIPI 3.67
is 170.242; the number of SNPs in HSPVdb (subsets 1 and 5) is
380.182
Database Number sequences Number of residues Size relative to IPI 3.69 ARFs? 0/1? Unk?
IPI (HUMAN v3.69) 87130 35200044 1.00 – –
MSIPI (HUMAN v3.67) 87040 42553286 1.21 ✓ ✓
PepHum 75237 176019757 5.00 ✓ ✓ ✓
HSPV 2634086 45422884 1.29 ✓ ✓ ✓
Rel. to set 5
HSPV subset 1 423015 8344552 0.18 ✓ ✓
HSPV subset 2 377269 7440614 0.16 ✓
HSPV subset 3 106379 2108989 0.05
HSPV subset 4 152125 3012927 0.07 ✓
HSPV subset 5 2634086 45422884 1.00 ✓ ✓ ✓
HSPV subset 6 2378073 41106669 0.90 ✓ ✓
HSPV subset 7 729721 12444311 0.27 ✓
HSPV subset 8 985734 16760526 0.37 ✓ ✓
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classified by the following criteria: (1) was the tandem
mass spectrum correctly identified by the search engine
(indicated by black and gray filling in the first column) for
each database? and (2) was the identification score above
(indicated by black filling in the second column for each
database) or below the Mascot significance threshold (cut-
off score)? Therefore, “the blacker the better”. The presence
(“Pr”) of each peptide in the particular database is indicated
by “Y” in the appropriate column. Supplementary Table 1
shows the results of all searches performed with the test set
of 31 tandem mass spectra to the IPI 3.69, MSIPI 3.67,
PepHum, and HSPVdb.
From Table 2, it is immediately clear that the IPI
database is not useful for finding MiHA, since it lacks
essential variation information.
The PepHum database, based on expressed sequence
tags (ESTs) information, including ARFs, is relatively
large, by which relevant information for finding our
polymorphic epitopes is “diluted”, and consequently, a
serious amount of “noise” is generated, increasing the
chance of finding false positives. The consequence of this is
reflected in the outcome of the database search for
PepHum. The number of significantly scoring peptides is
only 5 as compared to the 19 peptides identified by our
HSPVdb, see also Fig. 1a. This low score is only partially
rescued by the number of correctly assigned peptides with a
score below the Mascot significance threshold. In addition,
ESTs may be more prone to experimental sequencing
errors, leading to occurrence of false SNPs.
The elegantly produced MSIPI does quite well, but also
here, most correct peptide hits are below the statistical
significance threshold score, which makes it hard to decide
if a hit is true or a false positive in a “non-test set” setting.
In addition, the MSIPI does not contain information from
ARFs and UTRs.
For the HSPVdb, out of 31 MS/MS spectra, 19 are iden-
tified correctly above the Mascot significance threshold,
while another 7 are also correctly identified, but below the
significance threshold. Only three tandem mass spectra were
wrongly assigned (false positives).
These wrong assignments are caused by the poor quality
of the tandem mass spectra of these peptides, due to
intrinsic peptide properties. To two tandem mass spectra, no
match was assigned. These tandem mass spectra represent
two peptides, “YIGEVLVSV”, which yields a bad mass
spectrum and “RPHAIRRPLAL”, which is not present in
the HSPVdb subset, because it is derived from a SNP not
found in the dbSNP database. The HSPVdb, designed to
reduce non-informative sequence information, outperforms
the other databases.
Next to the size of the database, relieving the accuracy
condition from 1 to 50 ppm (Fig. 1b) has a detrimental effect
on both the number of correctly assigned peptides above and
below the Mascot significance threshold. This effect can
even lead to a false-positive score, as illustrated by a high
and significant Mascot score of 63 (!) for MS/MS/query #6
(in HSPVdb, 50 ppm), see supplementary Table 1a. This
result emphasizes the value of high mass accuracy.
So far, the good performance in the MS/MS-based
identification of T cell epitopes of HSPVdb can be
attributed to the compact nature and the special focus on
polymorphic peptides. A reduced database size directly
translates to a lower noise level in the database search,
which is especially important in high-throughput T cell
epitope elucidation, where search space limiting constraints
like an enzyme cleavage site cannot be used. Another
parameter affecting search quality is mass accuracy, which
is also proven to be a prominent factor in avoiding false
positives.
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To further improve the quality of our HSPVdb, we
focused on the quality of the SNPs in dbSNP, since we
noted that the reported frequency of a substantial number of
SNPs in dbSNP is “0” or “1” or “unknown”. This made us
decide to study a random set of 52 SNPs with no frequency
reported in dbSNP. We developed a SNP assay to screen a
random HLA-A*02-positive Dutch donor population using
the KASPar assay (92 DNA samples) and a SNP array (192
DNA samples). In our test population, 46 out of the 52
SNPs (90%) were not polymorphic, having an allele
frequency of 1 or 0 in the SNP assays. Two SNPs (4%)
were very rare (allele frequencies of 0.97, and 0.99), and 4
SNPs (8%) had a reasonable distribution in our population
(0.77; 0.70; 0.20; 0.13).
A large number of reported “SNPs” in dbSNP is
apparently not polymorphic, thereby contaminating our
proteomics approach and the chance of finding suitable
patient/donor MiHA pairs. Therefore, since reduction of the
search space greatly enhances the chance of finding true
positives in database searches, we decided to test our
HSPVdb after removal of either “unknowns” or “0” and
“1”, or both. The results are shown in supplementary
Table 1b. Subset 3, the leanest form of HSPVdb with both
“0” and “1” and “unknown frequency” SNPs removed and
without ARFs, is reduced to only one fourth of its original
size. Therefore, the significance threshold is clearly lowered
(from 28 to 22 for 1-ppm mass accuracy), increasing the
chance of finding true positives. In particular, those derived
from tandem mass spectra of relatively poor quality with
accompanying intrinsic low Mascot scores. Only one true
positive is lost, because its frequency is not reported in the
dbSNP. Similarly, the other subsets (subsets 1–8) of
HSPVdb have reduced significance thresholds (data not
shown). The application of these various forms of the
database can be adapted to the needs of the user.
So far, we have shown that the selective reduction of the
database size by removal of both the non-polymorphic
peptide stretches and the SNPs of limited value, leads to a
comprehensive high quality database file dedicated to
improving the elucidation of MiHA.
Database quality and inconsistencies
During this work, we discovered inconsistencies in the
number of SNPs included in several RefSeq and MSIPI
versions, see Fig. 2a and b.
The number of reported human SNPs dropped by 50%
going from RefSeq release 28 to release 30, and by more
than 50% in MSIPI going from version 37 to version 38.
We reported this in October 2008 to the respective database
producers who acknowledged there were problems and
improved their efforts. Recently, we encountered a problem
with the SNPs reported by 1000genomes.org in dbSNP
which is being solved. Therefore, we continued using
version 3.32 (on our website the HSPVdb version based on
either Refseq release 32 or release 40 can be chosen). We
would like to warn users for the status of the RefSeq with
respect to this. MSIPI, also being a secondary database,
suffered from the same errors during several versions, but
this has been repaired, starting from version 49, although a
strong decrease can be seen in version 3.67 (Fig. 2b). In
general, as a user of these databases, it is very hard to judge
the value of the database, so caution should be taken: newer
versions are not always better.
Application of HSPVdb to finding potential MiHA
presented in HLA on EBV-cells
To investigate the effects of application of our database to a
representative HLA-ligand elution experiment, we eluted
peptides from an EBV-LCL cell line (EBV-JY). After lysis,
affinity purification was performed with BB7.2 antibody
for HLA-A2, followed by separation of HLA and peptides.
Subsequently, the complex peptide pool was analyzed by
on-line nanoHPLC-tandem MS. The tandem mass spectra
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were matched against several databases for comparison, in
particular, MSIPI and various subsets of our HSPV
database.
Here, MSIPI is compared to the smallest subset of our
HSPV database without ARFs (subset 3) and with ARFs
included (subset 7), the advantages of which have been
illustrated for the test set described above. These trimmed
subsets do not include SNPs of which the frequencies in
dbSNP are reported to be 0/1 or unknown. By searching
against the smaller compact database containing all relevant
SNPs, intermediate scoring peptides appear in the database
search that would otherwise fall below the significance
threshold when matching tandem mass spectra against
larger databases.
This is illustrated by the number of intermediate
scoring peptides, i.e., those peptides that score below
the Mascot significance threshold when matching
against MSIPI, and are, therefore, peptides not found
otherwise. An additional 130 peptides were found for
subset 3 and an additional 400 for subset 7. These extra
peptides need to be checked for false positives (peptides
with tandem mass spectra that match better with non-
SNP containing peptides), and for the presence of a
SNP. The extra peptides found can, e.g., be evaluated by
application of netMHC. This approach, starting from
our small experimental elution experiment, yielded eight
peptides from subset 7 (including ARFs), and five peptides
from subset 3 with a netMHC score below 50 (i.e., a
stringent condition for strong binding). These peptides,
shown in Table 4, are currently evaluated as potential
MiHA.
All peptides found only by searching against the
dedicated HSPV database increase the chance of finding
relevant MiHA. The excellent annotation of the SNPs
reported in our HSPV database enables the user to directly
jump to the relevant information about the polymorphism, a
feature that was largely lacking so far.
The HSPV database described here is an integral part
of a complete peptidomics pipeline for finding therapeu-
tically useful MiHA, a strategy that is currently under
development.
Availability and web interface
A flat file with the content of the HSPV database can be
requested by sending an email to hspv@bioinformatics.nl.
A simple interactive query interface is available at: http://
srs.bioinformatics.nl/hspv/.
This web interface allows the biologist to query the
database for peptide sequences. It returns a list of RefSeq
mRNA entries that contain a continuous reading frame
encoding the query peptide, the start position of that
reading frame, the position of the encoding nucleotide Ta
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sequence with respect to any annotated CDS, and a
description of the variations if the peptide contains any,
see Fig. 3a. This is a great feature for the initial assessment
of the quality and potential usefulness of the output of our
database searches.
The richness of SNP information of our database is
shown in Fig. 3b, for the peptide “TLSELHCD” displaying
SAPs at every position in the peptide.
Conclusions
We have shown that selective reduction of the database size
by removal of both the non-polymorphic peptide stretches
and the non-polymorphic “SNPs” leads to a comprehensive
high quality database file dedicated to improving the
elucidation of MiHA.
Improvements in the quality and quantity of dbSNP
entries, among others by the 1000 genomes project (http://
www.1000genomes.org), if well controlled, will greatly
enhance the use of our database by reporting useful
frequencies and removal of spurious frequencies in the
current dbSNP releases.
The website (http://srs.bioinformatics.nl/hspv/) pro-
vides easy access to relevant information about SNPs by
its good annotation and hyperlinks incorporated in the
HSPVdb.
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Fig. 3 Screen shots show the output of a query for the peptides SVAPALALFPA (upper panel) and TLSELHCD (lower panel). It clearly
illustrates the effect of the large number of annotated variations at the amino acid level
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